EAM Global Investors LLC Trims Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

EAM Global Investors LLC cut its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 35.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,489 shares of the biopharmaceutical company's stock after selling 33,353 shares during the period. EAM Global Investors LLC's holdings in Insmed were worth $4,245,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jump Financial LLC bought a new position in Insmed during the fourth quarter valued at approximately $230,000. Mariner LLC lifted its holdings in shares of Insmed by 23.4% during the fourth quarter. Mariner LLC now owns 30,788 shares of the biopharmaceutical company's stock worth $2,126,000 after purchasing an additional 5,844 shares during the period. Summit Investment Advisors Inc. boosted its stake in shares of Insmed by 10.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 17,551 shares of the biopharmaceutical company's stock worth $1,212,000 after buying an additional 1,630 shares during the last quarter. Kennedy Capital Management LLC boosted its position in Insmed by 197.6% during the fourth quarter. Kennedy Capital Management LLC now owns 36,058 shares of the biopharmaceutical company's stock worth $2,489,000 after purchasing an additional 23,940 shares in the last quarter. Finally, F M Investments LLC acquired a new position in shares of Insmed during the 4th quarter worth approximately $2,954,000.

Insmed Trading Down 4.9 %

Shares of INSM stock traded down $3.56 during trading hours on Monday, hitting $69.09. 505,184 shares of the company's stock traded hands, compared to its average volume of 1,956,478. The stock's 50 day simple moving average is $75.34 and its 200 day simple moving average is $73.61. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a market cap of $12.56 billion, a PE ratio of -12.36 and a beta of 1.07. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, sell-side analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 33,055 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the transaction, the insider now directly owns 138,053 shares of the company's stock, valued at $11,168,487.70. This represents a 19.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 471,797 shares of company stock valued at $37,621,239 over the last 90 days. 3.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on INSM shares. JPMorgan Chase & Co. increased their target price on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. Finally, Stifel Nicolaus decreased their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average price target of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.